Rapid Generation of Neutralizing Antibody Responses i

Cell Reports Medicine
1, 100040
DOI: 10.1016/j.xcrm.2020.100040

Citation Report

#	Article	IF	Citations
1	COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Advances, 2020, 4, 4278-4281.	2.5	23
2	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. Journal of Clinical Virology, 2020, 131, 104611.	1.6	61
3	Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?. Frontiers in Immunology, 2020, 11, 567710.	2.2	49
4	Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1777-1794.	1.2	57
5	Seroprevalence of antiâ€SARSâ€CoVâ€2 antibodies in COVIDâ€19 patients and healthy volunteers up to 6 months post disease onset. European Journal of Immunology, 2020, 50, 2025-2040.	1.6	188
6	A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. SN Comprehensive Clinical Medicine, 2020, 2, 2059-2066.	0.3	8
7	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	7.1	427
8	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell, 2020, 183, 996-1012.e19.	13.5	1,494
9	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Reports Medicine, 2020, 1, 100099.	3.3	61
10	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nature Reviews Immunology, 2020, 20, 709-713.	10.6	229
11	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology, 2020, 21, 1506-1516.	7.0	563
12	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 2020, 17, 543-558.	6.1	999
13	Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies. Journal of Clinical Microbiology, 2020, 58, .	1.8	90
14	COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and Experimental Immunology, 2020, 202, 149-161.	1.1	155
15	Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature Communications, 2020, 11, 6044.	5.8	196
16	Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges. IScience, 2020, 23, 101406.	1.9	144
17	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell, 2020, 182, 1295-1310.e20.	13.5	1,726
18	Convalescent Plasma Therapy for COVID-19: State of the Art. Clinical Microbiology Reviews, 2020, 33, .	5.7	94

#	Article	IF	Citations
19	Kinetics and isotype assessment of antibodies targeting the spike protein receptorâ€binding domain of severe acute respiratory syndromeâ€coronavirusâ€2 in COVIDâ€19 patients as a function of age, biological sex and disease severity. Clinical and Translational Immunology, 2020, 9, e1189.	1.7	38
20	Is Herd Immunity Against SARS-CoV-2 a Silver Lining?. Frontiers in Immunology, 2020, 11, 586781.	2.2	25
21	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
22	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Science Advances, 2020, 6, .	4.7	128
23	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology, 2020, 52, 801-808.	0.3	71
24	Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics, 2020, 146, .	1.0	113
25	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. Cell Host and Microbe, 2020, 28, 516-525.e5.	5.1	219
26	Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?. Biology, 2020, 9, 243.	1.3	6
27	Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. Frontiers in Immunology, 2020, 11, 2130.	2.2	77
28	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. Viruses, 2020, 12, 987.	1.5	20
29	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	2.2	190
30	Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. Frontiers in Medicine, 2020, 7, 603996.	1.2	9
31	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	5.6	244
32	Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARSâ€CoVâ€2 Neutralizing Antibodies. Current Protocols in Immunology, 2020, 131, e116.	3.6	111
33	Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility. Virologica Sinica, 2020, 35, 793-802.	1.2	24
34	Convalescent plasma â€“ this is no time for competition. Transfusion, 2020, 60, 1644-1646.	0.8	5
35	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity, 2020, 114, 102506.	3.0	248
36	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 197-205.	1.9	216

#	Article	IF	Citations
37	SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. Journal of Infectious Diseases, 2021, 223, 62-71.	1.9	55
38	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	1.0	86
39	Duration of anti-SARS-CoV-2 antibodies much shorter in India. Vaccine, 2021, 39, 886-888.	1.7	6
40	The scientific and ethical feasibility of immunity passports. Lancet Infectious Diseases, The, 2021, 21, e58-e63.	4.6	82
41	Viral infection neutralization tests: A focus on severe acute respiratory syndromeâ€coronavirusâ€2 with implications for convalescent plasma therapy. Reviews in Medical Virology, 2021, 31, e2170.	3.9	45
42	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. Indian Journal of Medical Research, 2021, 153, 64.	0.4	5
44	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cellular and Molecular Immunology, 2021, 18, 318-327.	4.8	270
45	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
46	Persistent cellular immunity to SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	115
47	Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. Communications Biology, 2021, 4, 267.	2.0	25
48	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, 371, .	6.0	2,268
51	Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings. Open Forum Infectious Diseases, 2021, 8, ofab061.	0.4	8
52	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory Healthcare Personnel (COPE) study. Infection Control and Hospital Epidemiology, 2022, 43, 381-386.	1.0	10
54	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	2.2	117
56	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nature Communications, 2021, 12, 844.	5.8	146
59	The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life, 2021, 11, 144.	1.1	21
62	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	13.5	1,364
63	An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay. Immunohematology, 2021, 37, 33-43.	0.2	0

#	Article	IF	Citations
64	Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel. JAMA Network Open, 2021, 4, e211283.	2.8	112
65	Development of neutralizing antibody responses against SARSâ€CoVâ€2 in COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 4334-4341.	2.5	7
67	Comparison of Antibody Class-Specific SARS-CoV-2 Serologies for the Diagnosis of Acute COVID-19. Journal of Clinical Microbiology, 2021, 59, .	1.8	23
68	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. Biology, 2021, 10, 208.	1.3	16
69	What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1). Annals of Internal Medicine, 2021, 174, 828-835.	2.0	2
70	COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers in Pharmacology, 2021, 12, 633680.	1.6	64
71	Antibody Response After SARS-CoV-2 Infection and Implications for Immunity. Annals of Internal Medicine, 2021, 174, 811-821.	2.0	86
72	SARS-CoV-2 in severe COVID-19 induces a TGF-Î²-dominated chronic immune response that does not target itself. Nature Communications, 2021, 12, 1961.	5.8	145
73	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	2.2	33
74	The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. Journal of Clinical Microbiology, 2021, 59, .	1.8	73
75	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 632814.	2.2	62
76	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	6.0	468
77	Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clinical and Experimental Immunology, 2021, 204, 310-320.	1.1	62
78	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity, 2021, 54, 542-556.e9.	6.6	72
79	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. Med, 2021, 2, 313-320.e4.	2.2	77
80	Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System. Public Health Reports, 2021, 136, 361-367.	1.3	15
81	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature, 2021, 594, 253-258.	13.7	253
82	Immune Responses to SARS CoV-2: A Scoping Review. European Journal of Medical and Health Sciences, 2021, 3, 10-16.	0.1	0

#	Article	IF	Citations
83	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	5.1	87
85	Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease. BioScience Trends, 2021, 15, 93-99.	1.1	13
86	Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. Frontiers in Immunology, 2021, 12, 580147.	2.2	2
88	Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 105, 474-481.	1.5	6
89	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine, 2021, 180, 106355.	1.3	25
90	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. PLoS Pathogens, 2021, 17, e1009064.	2.1	21
91	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	3.9	58
94	Diagnostic significance of detecting neutralizing antibodies to SARS-CoV-2. AktualÊ¹naÃ¢ InfektologiÃ¢, 2021, 9, 24-27.	0.1	3
95	Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Viral Immunology, 2021, 34, 201-209.	0.6	31
97	Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies. Expert Review of Molecular Diagnostics, 2021, 21, 363-370.	1.5	37
98	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. International Immunopharmacology, 2021, 93, 107364.	1.7	54
99	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host and Microbe, 2021, 29, 516-521.e3.	5.1	199
100	Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2. Frontiers in Immunology, 2021, 12, 660019.	2.2	15
101	Are We Forgetting About IgA? A Reâ€examination of Coronavirus Disease 2019 Convalescent Plasma. Transfusion, 2021, 61, 1740-1748.	0.8	16
103	Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Human Vaccines and Immunotherapeutics, 2021, 17, 3481-3483.	1.4	28
104	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. Viruses, 2021, 13, 962.	1.5	17
105	Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA - Journal of the American Medical Association, 2021, 325, 1896.	3.8	125
106	One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. ImmunoHorizons, 2021, 5, 322-335.	0.8	19

#	Article	IF	Citations
107	Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Reports Medicine, 2021, 2, 100287.	3.3	183
109	Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain. Journal of Immunology, 2021, 206, 2605-2613.	0.4	7
111	Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA. Journal of Clinical Microbiology, 2021, 59, .	1.8	22
112	Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System. Annals of Internal Medicine, 2021, 174, 649-654.	2.0	77
113	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 684014.	2.2	37
116	Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	9
117	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	2.2	17
118	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clinical Microbiology Reviews, 2021, 34, .	5.7	205
119	Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease. Frontiers in Immunology, 2021, 12, 695230.	2.2	12
121	Advances in Neutralization Assays for SARSâ€CoVâ€2. Scandinavian Journal of Immunology, 2021, 94, e13088.	1.3	40
122	Re-infection of SARS-CoV-2: A case in a young dental healthcare worker. Journal of Infection and Public Health, 2021, 14, 685-688.	1.9	6
123	SARS-CoV-2 infection in fully vaccinated healthcare workers. International Journal of Infectious Diseases, 2022, 114, 183-184.	1.5	3
124	Lymphopenia and IgG2 subclass deficiency in patients with severe COVID-19 pneumonia. African Journal of Thoracic and Critical Care Medicine, 2021, 27, 41.	0.3	2
125	Key features of tests for detection of SARS-CoV2 antibodies. Medical Alphabet, 2021, , 13-17.	0.0	0
127	Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. International Journal of Infectious Diseases, 2021, 107, 221-227.	1.5	36
128	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host and Microbe, 2021, 29, 917-929.e4.	5.1	132
129	Immune responses and therapeutic challenges in paediatric patients with newâ€onset acute myeloid leukaemia and concomitant COVIDâ€19. British Journal of Haematology, 2021, 194, 549-553.	1.2	5
130	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. Virology, 2021, 558, 13-21.	1.1	24

#	Article	IF	Citations
131	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. Journal of Immunology, 2021, 207, 878-887.	0.4	30
133	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Science Immunology, 2021, 6, .	5.6	53
134	Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2. Clinical Infectious Diseases, 2022, 74, 1220-1229.	2.9	45
135	Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Reports Medicine, 2021, 2, 100329.	3.3	65
136	Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Scientific Reports, 2021, 11, 14917.	1.6	23
137	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology, 2021, 559, 1-9.	1.1	29
138	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses, 2021, 13, 1371.	1.5	11
139	Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Obstetrics and Gynecology, 2021, 138, 189-197.	1.2	51
140	Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Medicine, 2021, 19, 169.	2.3	52
142	Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). Experimental Biology and Medicine, 2021, 246, 2543-2552.	1.1	20
143	Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. Trends in Microbiology, 2021, 29, 648-662.	3.5	43
144	Rapid and costâ€effective process based on insect larvae for scaleâ€up production of SARSâ€COVâ€2 spike protein for serological COVIDâ€19 testing. Biotechnology and Bioengineering, 2021, 118, 4129-4137.	1.7	6
145	The Emergence of SARS-CoV-2 within the Dog Population in Croatia: Host Factors and Clinical Outcome. Viruses, 2021, 13, 1430.	1.5	18
146	Case Report: Analysis of Inflammatory Cytokines IL-6, CCL2/MCP1, CCL5/RANTES, CXCL9/MIG, and CXCL10/IP10 in a Cystic Fibrosis Patient Cohort During the First Wave of the COVID-19 Pandemic. Frontiers in Pediatrics, 2021, 9, 645063.	0.9	3
147	Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. Molecular Immunology, 2021, 135, 268-275.	1.0	15
148	Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009551.	1.3	25
149	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and TÂcells. Cell Reports Medicine, 2021, 2, 100354.	3.3	316
150	Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays. Cells, 2021, 10, 1843.	1.8	13

#	Article	IF	Citations
152	Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donorâ€“recipient differences in concentration of neutralizing antibodies. Clinical Microbiology and Infection, 2021, 27, 987-992.	2.8	6
153	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. MSphere, 2021, 6, e0027521.	1.3	36
154	Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0256482.	1.1	16
155	Putative Role of Vitamin D for COVID-19 Vaccination. International Journal of Molecular Sciences, 2021, 22, 8988.	1.8	32
157	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 2021, 6, 317.	7.1	68
158	Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa. Emerging Infectious Diseases, 2021, 27, 2009-2016.	2.0	12
159	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. International Immunopharmacology, 2021, 97, 107622.	1.7	14
160	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathogens, 2021, 17, e1009772.	2.1	74
161	Refining the N-Termini of the SARS-CoV-2 Spike Protein and Its Discrete Receptor-Binding Domain. Journal of Proteome Research, 2021, 20, 4427-4434.	1.8	4
162	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Scientific Reports, 2021, 11, 17642.	1.6	41
163	Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115537.	0.8	8
164	Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. PLoS ONE, 2021, 16, e0257351.	1.1	6
166	Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. Viral Immunology, 2021, 34, 708-713.	0.6	2
167	COVID-19 and obesity: fighting two pandemics with intermittent fasting. Trends in Endocrinology and Metabolism, 2021, 32, 706-720.	3.1	23
168	Immunity Profiling of COVID-19 Infection, Dynamic Variations of Lymphocyte Subsets, a Comparative Analysis on Four Different Groups. Microorganisms, 2021, 9, 2036.	1.6	19
169	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. Innate Immunity, 2021, 27, 423-436.	1.1	6
170	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Frontiers in Immunology, 2021, 12, 737083.	2.2	18
171	Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Frontiers in Immunology, 2021, 12, 742941.	2.2	81

#	Article	IF	Citations
172	Longitudinal observation of antibody responses for 14Âmonths after SARS-CoV-2 infection. Clinical Immunology, 2021, 230, 108814.	1.4	26
173	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
174	Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study. International Immunopharmacology, 2021, 98, 107893.	1.7	15
175	Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks. Microbiology Spectrum, 2021, 9, e0022421.	1.2	8
176	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. International Reviews of Immunology, 2022, 41, 393-413.	1.5	13
177	Evaluation of spike protein antigens for SARS-CoV-2 serology. Journal of Virological Methods, 2021, 296, 114222.	1.0	10
179	Comprehensive analysis of COVID-19 during pregnancy. Biochemical and Biophysical Research Communications, 2021, 538, 180-186.	1.0	67
181	SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. Journal of Infectious Diseases, 2021, 223, 1120-1131.	1.9	27
182	Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins. Transplantation, 2021, 105, 79-89.	0.5	40
202	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. Blood Cancer Discovery, 2021, 2, 9-12.	2.6	20
203	Convalescent plasma antiâ€“SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. Journal of Clinical Investigation, 2020, 130, 6728-6738.	3.9	172
204	Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 2020, 15, e0244126.	1.1	269
205	Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and correlation with plaque reduction neutralization titer. Clinical Chemistry and Laboratory Medicine, 2020, 58, e247-e249.	1.4	12
208	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Eurosurveillance, 2020, 25, .	3.9	17
209	Comparative analysis of candidate vaccines to prevent covid 19 pandemic. E3S Web of Conferences, 2021, 309, 01038.	0.2	0
211	Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children. Frontiers in Immunology, 2021, 12, 753435.	2.2	13
212	Clinical and immunological characteristics in COVID-19 convalescent patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2669-2676.	1.3	1
213	Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. Heliyon, 2021, 7, e08140.	1.4	7

#	Article	IF	Citations
214	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Biomedicine and Pharmacotherapy, 2021, 144, 112282.	2.5	10
216	Immune interventions in COVID-19: a matter of time?. Mucosal Immunology, 2022, 15, 198-210.	2.7	14
217	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Npj Vaccines, 2021, 6, 128.	2.9	102
218	SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation. Frontiers in Immunology, 2021, 12, 767981.	2.2	36
221	Coronavirus antigens as targets of antibody responses. Clinics in Laboratory Medicine, 2021, 42, 97-109.	0.7	1
224	The Impact of COVID-19 Immunity in Vaccine Development. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	0
225	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. Npj Vaccines, 2021, 6, 143.	2.9	47
226	Application of SARS-CoV-2 Serology to Address Public Health Priorities. Frontiers in Public Health, 2021, 9, 744535.	1.3	4
227	Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area. Heliyon, 2021, 7, e08393.	1.4	2
228	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	1
230	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. Viruses, 2021, 13, 2391.	1.5	11
231	A runtime alterable epidemic model with genetic drift, waning immunity and vaccinations. Journal of the Royal Society Interface, 2021, 18, 20210648.	1.5	5
232	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72
233	Descriptive evaluation of antibody responses to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in plasma and gingival crevicular fluid in a nursing home cohortâ€"Arkansas, Juneâ€"August 2020. Infection Control and Hospital Epidemiology, 2022, 43, 1610-1617.	1.0	3
234	Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. Immuno, 2021, 1, 442-456.	0.6	7
236	Analysis of longâ€term antibody response in COVIDâ€19 patients by symptoms grade, gender, age, BMI, and medication. Journal of Medical Virology, 2022, 94, 1412-1418.	2.5	16
237	Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: A systematic review of evidence to support global policy-level actions and research. Global Health Journal (Amsterdam, Netherlands), 2021, , .	1.9	1
238	The Immunomodulatory Function of Vitamin D, with Particular Reference to SARS-CoV-2. Medicina (Lithuania), 2021, 57, 1321.	0.8	2

#	Article	IF	Citations
239	An overview of the ongoing challenges in SARS-CoV-2 global control. German Journal of Microbiology, 2021, 1, 1-18.	0.3	17
240	Neutralizing antibody: a savior in the Covid-19 disease. Molecular Biology Reports, 2022, 49, 2465-2474.	1.0	18
241	Humoral response to SARS-CoV-2 infection among liver transplant recipients. Gut, 2022, 71, 746-756.	6.1	11
242	Recruitment of highly cytotoxic CD8+ TÂcell receptors in mild SARS-CoV-2 infection. Cell Reports, 2022, 38, 110214.	2.9	19
243	Serological testing for COVID-19. Journal of Lung, Pulmonary & Respiratory Research, 2021, 8, 35-39.	0.3	0
244	Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19. Irish Journal of Medical Science, 2022, 191, 2833-2838.	0.8	1
245	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
246	Redox Homeostasis and Immune Alterations in Coronavirus Disease-19. Biology, 2022, 11, 159.	1.3	10
247	Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh. PLoS Neglected Tropical Diseases, 2022, 16, e0010102.	1.3	18
248	What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2). Annals of Internal Medicine, 2022, , .	2.0	1
249	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Reports Medicine, 2022, 3, 100528.	3.3	6
250	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science, 2022, 29, 1.	2.6	144
251	IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools. PLoS ONE, 2022, 17, e0262162.	1.1	23
252	Limited induction of SARS-CoV-2â€“specific T cell responses in children with multisystem inflammatory syndrome compared with COVID-19. JCI Insight, 2022, 7, .	2.3	17
253	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	3.3	18
254	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Reports, 2022, 38, 110318.	2.9	17
255	Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARSâ€CoVâ€2 Variants after Primary and Booster Immunization. International Journal of Infectious Diseases, 2022, 117, 97-102.	1.5	5
256	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. Scientific Reports, 2022, 12, 2077.	1.6	8

#	Article	IF	Citations
257	Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. Frontiers in Immunology, 2022, 13, 796481.	2.2	7
259	A Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader for SARS-CoV-2 Neutralizing Antibody Detection. Vaccines, 2022, 10, 271.	2.1	9
261	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. Clinical Biochemistry, 2022, 101, 19-25.	0.8	5
262	Deep dissection of the antiviral immune profile of patients with COVID-19. Communications Biology, 2021, 4, 1389.	2.0	9
263	SARS-CoV-2 Specific IgG Antibodies Persist Over a 12-Month Period in Oral Mucosal Fluid Collected From Previously Infected Individuals. Frontiers in Immunology, 2021, 12, 777858.	2.2	6
264	Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents. Frontiers in Immunology, 2021, 12, 797919.	2.2	13
265	Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210873.	0.5	4
266	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
268	T and B Cells Immune Response and the importance of vaccines Against SARS-CoV-2. Revista Bionatura, 2022, 7, 1-8.	0.1	0
269	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study. Infection Control and Hospital Epidemiology, 2022, , 1-8.	1.0	7
270	Serologic and Cytokine Signatures in Children With Multisystem Inflammatory Syndrome and Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofac070.	0.4	13
271	Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain. Journal of Virology, 2022, 96, e0025022.	1.5	10
272	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
273	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of Clinical Oncology, 2022, 40, 3057-3064.	0.8	31
274	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell Reports Medicine, 2022, 3, 100603.	3.3	27
275	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ, 2022, 10, e13083.	0.9	14
276	Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. International Journal of Molecular Sciences, 2022, 23, 2977.	1.8	4
277	Protective and pathogenic role of humoral responses in COVID-19. Journal of Microbiology, 2022, 60, 268-275.	1.3	4

#	Article	IF	Citations
278	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells, 2022, 11, 1182.	1.8	10
280	The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Journal of Immunological Methods, 2022, 503, 113244.	0.6	11
281	Analysis of Clinical Course and Vaccination Influence on Serological Response in COVID-19 Convalescents. Microbiology Spectrum, 2022, , e0248521.	1.2	0
282	INVESTIGATION AND LONGâ€TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVIDâ€19 DISEASE OF DIFFERENT CLINICAL SEVERITY. Journal of Medical Virology, 2022, , .	2.5	5
283	The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech). Scientific Reports, 2022, 12, 5999.	1.6	3
284	New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality. Exploration of Immunology, 0, , 432-439.	1.7	0
286	Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus. Journal of Clinical Medicine, 2021, 10, 5882.	1.0	4
288	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Medicine, 2021, 18, e1003868.	3.9	20
290	No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study. Scientific Reports, 2021, 11, 24198.	1.6	0
291	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. Frontiers in Immunology, 2021, 12, 790469.	2.2	15
292	Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods. Current Medical Science, 2021, 41, 1052-1064.	0.7	16
293	Evaluation of the Bactericidal Activity of Galectins. Methods in Molecular Biology, 2022, 2442, 517-531.	0.4	4
294	Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays. Analytical Chemistry, 2022, , .	3.2	7
295	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 2022, 13, 817345.	2.2	5
296	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
299	Impact of Covishield Vaccination in Terms of SARS CoV-2 Neutralizing Antibody Expression. Indian Journal of Clinical Biochemistry, 2022, , 1-8.	0.9	0
300	The Effect of Convalescent Plasma in Patients With Covid-19 in Intensive Care Unit. In Vivo, 2022, 36, 1342-1348.	0.6	0
301	Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Frontiers in Immunology, 2022, 13, 878812.	2.2	3

#	Article	IF	Citations
302	Opinion Polls and Antibody Response Dynamics of Vaccination with COVID-19 Booster Vaccines. Vaccines, 2022, 10, 647.	2.1	3
303	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	3.9	17
304	Myeloid-derived suppressor cells in COVID-19: A review. Clinical Immunology, 2022, 238, 109024.	1.4	14
305	Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study. Heliyon, 2022, 8, e09438.	1.4	2
306	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	6.6	74
307	Community-Based Cross-Sectional Study of the Relationship between Sars-Cov-2 Antibody Titres and Clinico-Epidemiological Profile of Population above 6 Years of Age in the Pimpri Chinchwad, Pune, Maharashtra. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.0	0
308	May IgG4-related disease be reactivated by SARS-CoV-2 infection?. Reumatologia, 2022, 60, 161-162.	0.5	3
311	Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Bindingâ€"Who Is Binding Who and Why?. International Journal of Molecular Sciences, 2022, 23, 6050.	1.8	9
312	Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Annals of Hematology, 2022, 101, 1825-1834.	0.8	7
313	Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques. IScience, 2022, 25, 104448.	1.9	7
314	Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo. Scientific Reports, 2022, 12, .	1.6	10
315	Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis. International Journal of Infectious Diseases, 2022, 122, 327-331.	1.5	1
316	Ag Nanoparticles with Ultrathin Au Shell-Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-Mode Detection of SARS-CoV-2 IgG. Analytical Chemistry, 2022, 94, 8466-8473.	3.2	56
317	Specificity and Confirmation of SARS-CoV-2 Serological Test Methods in Emergency Department Populations across the United States. journal of applied laboratory medicine, The, 2022, 7, 1424-1429.	0.6	2
318	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
319	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. International Journal of Translational Medicine, 2022, 2, 275-308.	0.1	1
320	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. MSphere, 2022, 7, .	1.3	16
321	Omicron (BA.1) and subâ€variants (BA.1.1, BA.2, and BA.3) of SARSâ€CoVâ€2 spike infectivity and pathogenicity: A comparative sequence and structuralâ€based computational assessment. Journal of Medical Virology, 2022, 94, 4780-4791.	2.5	133

#	Article	IF	Citations
322	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	7.0	84
323	The kinetics of IgG subclasses and contributions to neutralizing activity against SARSâ€CoVâ€2 wildâ€type strain and variants in healthy adults immunized with inactivated vaccine. Immunology, 2022, 167, 221-232.	2.0	10
324	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
325	SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites. Research, 2022, 2022, .	2.8	2
327	In COVID-19, antigen size lower or larger than 70 kDa modulates the sepsis and memory B cells. Exploration of Immunology, 0, , 442-453.	1.7	0
328	Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. IScience, 2022, 25, 104766.	1.9	13
329	Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection. JAMA Network Open, 2022, 5, e2221616.	2.8	39
330	Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. Biomedicine and Pharmacotherapy, 2022, 153, 113368.	2.5	6
332	Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nature Communications, 2022, 13, .	5.8	18
333	Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults. Journal of Virology, 2022, 96, .	1.5	13
334	Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease. BMC Infectious Diseases, 2022, 22, .	1.3	2
335	Immunoglobulin G and immunoglobulin M positivity in relation to coronavirus disease 2019 severity. Menoufia Medical Journal, 2022, 35, 378.	0.1	0
336	Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugalâ€"A Multicenter, Nationwide Study. Frontiers in Medicine, 0, 9, .	1.2	3
337	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. Scientific Reports, 2022, 12, .	1.6	3
338	New insights into human immune memory from <scp>SARSâ€CoV</scp> â€2 infection and vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	5
339	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
340	COVIDâ€19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95, .	2.5	24
341	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. Vaccines, 2022, 10, 1612.	2.1	14

#	Article	IF	Citations
342	Advancements in COVID- 19 Testing: An in-depth overview. Current Pharmaceutical Biotechnology, 2022, 23, .	0.9	0
343	COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine. PLoS ONE, 2022, 17, e0273323.	1.1	3
345	Role of the humoral immune response during COVID-19: guilty or not guilty?. Mucosal Immunology, 2022, 15, 1170-1180.	2.7	19
346	Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody. Science Advances, 2022, 8, .	4.7	25
347	Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. Minerva Gastroenterology, 0, , .	0.3	0
348	Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viruses, 2022, 14, 2419.	1.5	1
351	Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection. Medical Microbiology and Immunology, 2023, 212, 25-34.	2.6	4
352	Antibody Levels Poorly Reflect on the Frequency of Memory B Cells Generated following SARS-CoV-2, Seasonal Influenza, or EBV Infection. Cells, 2022, 11, 3662.	1.8	13
353	Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	1
355	SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort. Insights in Clinical and Cellular Immunology, 2022, 6, 008-013.	0.1	1
356	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	1.6	6
357	Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. Frontiers in Immunology, 0, 13, .	2.2	10
358	Rapid Quantification of SARS-CoV-2 Neutralising Antibodies Using Time-Resolved Fluorescence Immunoassay. Vaccines, 2022, 10, 2149.	2.1	3
359	Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood Cancer Discovery, 2023, 4, 106-117.	2.6	14
360	Anti-SARS-Cov-2â€‰S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement. Journal of Immunology Research, 2022, 2022, 1-12.	0.9	0
361	High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia. Vaccines, 2023, 11, 26.	2.1	3
362	Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes. Vaccines, 2022, 10, 2063.	2.1	1
363	Humoral and cellular immunity of twoâ€dose inactivated COVIDâ€19 vaccination in Chinese children: A prospective cohort study. Journal of Medical Virology, 2023, 95, .	2.5	2

#	Article	IF	Citations
365	Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests. Viruses, 2023, 15, 106.	1.5	3
366	Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naÃ¯ve adult Nigerians. PLoS ONE, 2023, 18, e0280276.	1.1	2
368	Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress. Vaccines, 2023, 11, 218.	2.1	4
369	SARS-CoV-2 infection and immune responses. AIMS Microbiology, 2023, 9, 245-276.	1.0	2
370	Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome. Viruses, 2023, 15, 454.	1.5	2
371	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. Tropical Medicine and Infectious Disease, 2023, 8, 185.	0.9	0
372	Longitudinal analysis of anti-SARS-CoV-2 neutralizing antibody (NAb) titers in vaccinees using a novel giant magnetoresistive (GMR) assay. Sensors and Actuators B: Chemical, 2023, 387, 133773.	4.0	1
373	Defending against SARS-CoV-2: The T cell perspective. Frontiers in Immunology, 0, 14, .	2.2	20
374	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. Viruses, 2023, 15, 426.	1.5	3
376	SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients. PLoS ONE, 2023, 18, e0276829.	1.1	4
377	Study of some immunological signatures and their association with COVID-19 in a sample of recovered Iraqi patients. Immunobiology, 2023, 228, 152348.	0.8	1
378	Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic. Infectious Diseases and Therapy, 2023, 12, 735-747.	1.8	1
379	SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses, 2023, 15, 558.	1.5	1
380	Immune Dysregulation in Acute SARS-CoV-2 Infection. Pathogens and Immunity, 2022, 7, 143-170.	1.4	2
381	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. Vaccines, 2023, 11, 545.	2.1	3
382	SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments. Microorganisms, 2023, 11, 580.	1.6	1
384	A Novel Optimized Perturbation-Based Machine Learning for Preserving Privacy in Medical Data. Wireless Personal Communications, 2023, 130, 1905-1927.	1.8	0
385	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. International Journal of Molecular Sciences, 2023, 24, 5352.	1.8	7

#	Article	IF	Citations
386	Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions. Biomedical Microdevices, 2023, 25, .	1.4	7
387	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
388	HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses, 2023, 15, 906.	1.5	4
390	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. Vaccines, 2023, 11, 832.	2.1	1
391	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. AIMS Microbiology, 2023, 9, 375-401.	1.0	4
392	Comparison of Kinetics of Antibody Avidity and IgG Subclassesâ€™ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine. Viruses, 2023, 15, 970.	1.5	1
415	Innovation-driven trend shaping COVID-19 vaccine development in China. Frontiers of Medicine, 2023, 17, 1096-1116.	1.5	0
416	Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chemical Papers, 2024, 78, 2123-2154.	1.0	0